Dorsavi Ltd. · ASX:DVL
Dorsavi — Shareholder Meeting (November 2016)
26 slides from Dorsavi's shareholder meeting presentation, Nov 29, 2016
Slide 1: 2016 Annual General Meeting – Chairman's Address and CEO Presentation
ABN: 15 129 742 409 For personal use only 29 November 2016 Market Announcements Office Level 4, Exchange Centre 20 Bridge Street SYDNEY NSW 2000 Dear Sir/Madam 2016 Annual General Meeting – Chairman’s Address and CEO Presentation We attach a copy of the Chairman’s address and the CEO’s presentation
Slide 2: Chairman's Address
dorsaVi Ltd For personal use only Annual General Meeting - 29 November 2016 Chairman’s Address Good morning ladies and gentlemen, My name is Herb Elliott and as Chairman of dorsaVi I am pleased to welcome you to our third Annual General Meeting as an ASX listed Company. It is now 10:00am. This is a
Slide 3: Chairman's Address (continued)
and ViPerform for the sports market, have all experienced significant growth across our markets in the US, Australia and the UK. The expansion of our product footprint is supported with substantial growth in revenue and we now have a clear roadmap to profitability. We experienced a 124% increase in
Slide 4: Chairman's Address (continued)
clinical trials is proving to be an attractive offering for these multinationals who rely on measurements of movement and muscle activity in costly clinical trials. The sporting market continues to provide rich data to inform our product For personal use only development. This data has been essentia
Slide 5: dorsaVi Ltd Annual General Meeting 2016
For personal use only dorsaVi Ltd ANNUAL GENERAL MEETING 2016 Commercial in Confidence
Slide 6: Disclaimer
// 2 DISCLAIMER This presentation does not constitute investment, legal, taxation or other advice and the For personal use only presentation does not take into account your investment objectives, financial situation or particular needs. You are responsible for forming your own opinions and conclusio
Slide 7: CEO's Address
// 3 For personal use only CEO’S ADDRESS DR. ANDREW RONCHI
Slide 8: 2016 in Review – Highlights from an Exceptional Year
2016 IN REVIEW – HIGHLIGHTS FROM AN EXCEPTIONAL YEAR // 4 1. Grew revenue 2.3 times from $1.35M to 3.0M, reduced expenditure by $1.4M For personal use only 2. Successful launch of OHS ViSafe product into the UK and US markets with plan for annuity revenue 3. Achieved strong growth in clinical & spor
Slide 9: Revenue Up 2.3 Times on Lower Cost Base
// 5 1. REVENUE UP 2.3 TIMES ON LOWER COST BASE For personal use only dorsaVi Customer Revenue 2013 2014 2015 2016 Q1 2017 3,000 Revenue 398,607 529,380 1,358,218 3,019,000 1,004,000* EBITDA (2,148,749) (3,852,593) (8,684,709) (5,915,567) N/A 2,500 1,008 Loss from (1,659,235) (3,562,024) (8,036,161)
Slide 10: Strong Global Growth
// 6 STRONG GLOBAL GROWTH dorsaVi Sales Revenue For personal use only $2.0M $1.8M $1.6M $1.4M $1.2M Q4 $1.0M Q3 Q2 $0.8M Q1 $0.6M $0.4M $0.2M $0.0M FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 AU UK US
Slide 11: Successful Launch of OHS Product into US & UK
// 7 2. SUCCESSFUL LAUNCH OF OHS PRODUCT INTO US & UK For personal use only • Work injuries cost $250B p.a. (US) • Large untapped market with appetite for data • Unique IP leading to reduced injuries & costs • Interventions involving: • Job assessment • Equipment change • Pre-employment screening •
Slide 12: Insights from the Field Never Seen Before
// 8 INSIGHTS FROM THE FIELD NEVER SEEN BEFORE For personal use only Putting ‘Train Stop’ to gauge Remove ‘Train Stop’
Slide 13: Compelling Offering Leading to Annuity Revenue
// 9 COMPELLING OFFERING LEADING TO ANNUITY REVENUE For personal use only Problem for major corporates: • Lack of visibility on injuries and costs • Poor ability to understand and change issues dorsaVi offering: • ViSafe projects (real data from the field) • Provides insights, risk matrix and soluti
Slide 14: Achieved Strong Growth in Clinical & Sports
// 10 3. ACHIEVED STRONG GROWTH IN CLINICAL & SPORTS For personal use only 10 devices in FY15 80 devices in FY16 160 devices in 25 devices added in Q1 FY17 the market 24,000 physios (0.5% penetration) 85 devices in the market 48,000 physios 105 devices in the market 284,000 physical therapists
Slide 15: Clinical Platform to Manage Data, Reports and Communication
// 11 CLINICAL PLATFORM TO MANAGE DATA, REPORTS AND COMMUNICATION For personal use only Insurer PATIENT REPORTS AND DATA $ Doctor Employer Patient Specialist Physio Hospital Live Assessment Live Training Monitoring Biofeedback Exercises Reports
Slide 16: Signed with Scale Partners in the US & UK
// 12 4. SIGNED WITH SCALE PARTNERS IN THE US & UK For personal use only Targeting large and company-owned franchise networks • UK – YPP • US – Relationship with Select Medical Collaborative product development • Product commercially released: ViPerform AMI
Slide 17: Launched Agent Model for Rapid Revenue Growth
// 13 5. LAUNCHED AGENT MODEL FOR RAPID REVENUE GROWTH For personal use only Stages of OHS ViSafe work Scalable model: • Direct sales representatives in key markets • Sales partnerships with agents (win work & provide assessors) • Insurers and Insurance Brokers • Centralised analysis
Slide 18: Imminent Release of V6 Sensors – Game Changer
// 14 6. IMMINENT RELEASE OF V6 SENSORS – GAME CHANGER For personal use only
Slide 19: Market Excited by the Ease of Application
// 15 MARKET EXCITED BY THE EASE OF APPLICATION For personal use only Launch of myViSafe™ New cloud-based New cloud-based • Mini sensors clinical application for: clinical application for: • Manual Handling App • Running • Low Back • Video training • Knee • Walking • Pre employment screening • Funct
Slide 20: Existing Reimbursement Codes Supporting US Roll Out
// 16 7. EXISTING REIMBURSEMENT CODES SUPPORTING US ROLL OUT For personal use only • Initial target of $35 per session through existing reimbursement code 97750 • Billing multiple codes per session (Average billing >$150 per session) • Relationships building with groups like Select Medical and other
Slide 21: Reimbursement Strategy Progressed with Registry
// 17 8. REIMBURSEMENT STRATEGY PROGRESSED WITH REGISTRY For personal use only • US-based patient registry launched for low back pain to support reimbursement strategy • Low Back Registry will recruit over 1,500 US-based low back pain patients in the first 18 months • Initial 3 sites, headed by Wash
Slide 22: Incentive Program to Reward Exceptional Performance
// 18 9. INCENTIVE PROGRAM TO REWARD EXCEPTIONAL PERFORMANCE For personal use only • Strong Senior Management team with excellent experience • 3 year program to reward growth on a lean cost base Director & CEO Andrew Ronchi CFO CIO CPO CMO Head of Sales and Head of Sales and Head of Sales and Damian
Slide 23: Commercial Pilots with World Leaders
// 19 10. COMMERCIAL PILOTS WITH WORLD LEADERS For personal use only • • Unique insights coming from these commercial research projects Each project will lead to multiple new publications and potential new IP 65+ RESEARCH PROJECTS • 45,000 individual data sets and building daily • Medical device and
Slide 24: Looking Forward – A Solid Foundation for Growth
LOOKING FORWARD – A SOLID FOUNDATION FOR GROWTH // 20 For personal use only • Signing of additional OHS agents to scale revenue • Launch of myViSafe into OHS market – building annuity revenues • Launch of app-based sensors & platform into the clinical market • Publication of health economic evaluati
Slide 25: dorsaVi Ltd Annual General Meeting 2016
For personal use only // 21 dorsaVi Ltd ANNUAL GENERAL MEETING 2016 Commercial in Confidence
Slide 26: dorsaVi – Andrew Ronchi, Chief Executive Officer
// 22 dorsaVi™ For personal use only Andrew Ronchi PhD (Eng), B.App.Sci (Physio) Chief Executive Officer Level 1, 120 Jolimont Road, East Melbourne, Victoria 3002 Office: +61 9652 2192 | Mobile: +61 417 882 267 ar@dorsaVi.com | dorsaVi.com